OCS
HealthcareOculis Holding AG
$19.75
$-0.25 (-1.25%)
Jan 5, 2026
Price History (1Y)
Analysis
Oculis Holding AG is a biotechnology company operating in the healthcare sector. With a market capitalization of $1.14B, it is a relatively large entity with 49 employees. The company's financial health reveals significant losses, as evidenced by a net income of -$104,098,000 and an EBITDA of -$77,789,000 over the trailing twelve months. Its profitability margins are also negative, with gross margin, operating margin, and profit margin all at 0.0%. Return on equity stands at -92.2%, and return on assets is -33.4%. The company's balance sheet indicates a small amount of debt ($2.47M) compared to its cash reserves ($145.18M), resulting in a debt-to-equity ratio of 1.89. The valuation context for Oculis Holding AG shows a forward P/E of -8.59 and an EV/EBITDA of -11.63, indicating potential undervaluation based on past performance. The company's revenue growth rate is 12.5% year-over-year, but its earnings growth rate is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Visit website →Key Statistics
- Market Cap
- $1.14B
- P/E Ratio
- N/A
- 52-Week High
- $23.08
- 52-Week Low
- $14.00
- Avg Volume
- 111.46K
- Beta
- 0.14
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Switzerland
- Employees
- 49